The global lipopolysaccharides immunoassays market size was estimated to be US$ 1.24 billion in 2021 and is expected grow at a CAGR of 3.4% between 2023 to 2032.
Lipopolysaccharides immunoassays are predicted to experience opportunistic expansion. The emergence of point-of-care test kits for lipopolysaccharide immunoassays is correlated to this growth. This strategy is used in numerous industries. Given the strong correlation between P. gingivalis and other serious health issues, including cardiovascular disease and the neurodegenerative Alzheimer's disease, the quantitative analysis of lipopolysaccharide produced by this bacterium has emerged as a key marker for both dental health and the general body health system.
In the years ahead, lipopolysaccharide immunoassays are anticipated to become extremely important for the detection of LPS. One key driver of this growth would be the rising burden of infectious diseases. Due to the increasing impact of P. gingivalis LPS, there is a clear market demand for an unique point-of-care device that can be applied to both routine PG LPS level monitoring and early diagnosis. Traditional qualitative identification of bacterial biomarkers typically uses the well-known PCR technique, which requires qualified professionals and requires investing a lot of time in a laboratory.
Several advanced techniques, such as the usage of lipid bilayers, waveguide technology, aptamers, anti-microbials, synthetic polymers, optical immunoassays, electrochemical impedance spectroscopy (EIS), and in vitro assays, have been developed for the detection of lipopolysaccharides. The market for lipopolysaccharides immunoassays as a whole is constrained by the lack of alternative methods of lipopolysaccharide detection.
Since the outbreak of the novel coronavirus pandemic in 2020, interest in testing for infectious diseases has increased. As a result, the sales and production of immunoassay kits and reagents have surged, and the market is expected to grow rapidly over the next years as a result of innovations in clinical research methods.
By Product Type:
By End User:
The global lipopolysaccharides immunoassays market is estimated to exhibit a CAGR of 3.4% between 2023 to 2032.
The lipopolysaccharides immunoassays market size was estimated to be US$ 1.24 billion in 2021.
Increasing adoption of immunoassay test kits around the world will drive lipopolysaccharides immunoassays market growth.
Major players in the global lipopolysaccharides immunoassays market are BioChek(BIOTECON Diagnostics), AdVnt Biotechnologies, Fisher Scientific (THERMO), Bio-Techne, Response Biomedical, New Horizons Diagnostic Corporation and others.
Based on assay type, the lipopolysaccharides immunoassays market is segmented into ELISA, FIA, CLIA, LFA and Others.
Copyright © 2023 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved